INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71101, 'Clonazepam', 'Nelfinavir', 'Moderate', 'Nelfinavir competitively inhibits the CYP450 3A4 isoenzyme and may interfere with the metabolism of some benzodiazepines.', 'DDInter', 'Caution is advised if benzodiazepines are administered with nelfinavir. Patients should be monitored for the possibility of potentially serious and/or life threatening events (e.g. prolonged sedation, respiratory depression) associated with the accumulation of these agents.', 'Metabolism', 'Caution is advised if benzodiazepines are administered with nelfinavir.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71188/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More', 'Ethotoin, Brivaracetam, Rufinamide, Gabapentin, Topiramate, Ezogabine, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Lamotrigine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71102, 'Clonazepam', 'Nevirapine', 'Moderate', 'Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4. The proposed mechanism is increased clearance due to nevirapine-mediated induction of CYP450 3A4.', 'DDInter', 'Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates. Dosage adjustments as well as clinical and laboratory monitoring of coadministered drugs should be considered whenever nevirapine is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71189/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More', 'Brivaracetam, Topiramate, Ezogabine, Methylphenobarbital, Lacosamide, Levetiracetam, Ethotoin, Rufinamide, Paramethadione, Fosphenytoin, Vigabatrin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71103, 'Clonazepam', 'Nilotinib', 'Moderate', 'Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes. The mechanism is decreased clearance via these routes due to inhibition by nilotinib.', 'DDInter', 'Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71190/', '', 'Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Perampanel, Methsuximide, Phensuximide, Lamotrigine, More', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71104, 'Clonazepam', 'Nimodipine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71191/', '', 'Nisoldipine', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71105, 'Clonazepam', 'Nitroglycerin', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71192/', '', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71106, 'Clonazepam', 'Nitroprusside', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71193/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71107, 'Clonazepam', 'Nortriptyline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking clonazepam and tricyclic antidepressants.', 'DDInter', 'Patients should be monitored for excessive or prolonged CNS and respiratory depression. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, or confusion) and counseled to avoid activities requiring alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Patients should be monitored for excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71194/', '', 'St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71108, 'Clonazepam', 'Olanzapine', 'Major', 'The safety and efficacy of intramuscular olanzapine administered in combination with benzodiazepines have not been established. CNS- and/or cardiorespiratory-depressant effects may be increased during concomitant use of olanzapine and benzodiazepines, especially in elderly or debilitated patients.', 'DDInter', 'Caution is necessary when olanzapine is used in combination with benzodiazepines. Ambulatory patients should be made aware of the possibility of additive CNS effects and counseled to avoid activities requiring mental alertness until they know how these agents affect them. They should also be advised to avoid rising abruptly from a sitting or recumbent position and to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting. Concomitant administration of IM olanzapine and parenteral benzodiazepine has not been studied and is therefore not recommended. Patients given this combination when necessary should be closely monitored for excessive sedation and cardiorespiratory depression.', 'Synergism', 'Caution is necessary when olanzapine is used in combination with benzodiazepines.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71195/', '', 'Amisulpride, Pimavanserin', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71109, 'Clonazepam', 'Oliceridine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71196/', '', 'Lacosamide', 'Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71110, 'Clonazepam', 'Olopatadine (nasal)', 'Moderate', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.', 'DDInter', 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71197/', '', 'Fenfluramine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71111, 'Clonazepam', 'Opicapone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71198/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71112, 'Clonazepam', 'Opium', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71199/', '', 'Lacosamide', 'Eluxadoline, Diphenoxylate, Difenoxin, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71113, 'Clonazepam', 'Orphenadrine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71200/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71114, 'Clonazepam', 'Oxcarbazepine', 'Moderate', 'Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.', 'DDInter', 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71201/', '', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 'Oxcarbazepine, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71115, 'Clonazepam', 'Oxtriphylline', 'Minor', 'Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71202/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Mepolizumab, Roflumilast, Bromotheophylline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71116, 'Clonazepam', 'Oxycodone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71203/', '', 'Naloxone', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71117, 'Clonazepam', 'Oxymorphone', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71204/', '', 'Lacosamide', 'Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71118, 'Clonazepam', 'Ozanimod', 'Moderate', 'Limited clinical data suggest that concomitant use of clonazepam with monoamine oxidase inhibitors (MAOIs) may precipitate a hypertensive and/or flushing reaction. The mechanism of interaction has not been established. Phenelzine has been specifically implicated. Data for other combinations of MAOIs and benzodiazepines are not available.', 'DDInter', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine. Patients should be advised to notify their physician if they develop severe headaches or flushing.', 'Others', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71205/', '', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71119, 'Clonazepam', 'Paliperidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71206/', '', 'Lacosamide', 'Amisulpride, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71120, 'Clonazepam', 'Pancuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', 'DDInter', 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71207/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71121, 'Clonazepam', 'Paraldehyde', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71208/', '', 'Lacosamide, Paramethadione, Phensuximide, Phenacemide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71122, 'Clonazepam', 'Paroxetine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71209/', '', 'St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71123, 'Clonazepam', 'Pemoline', 'Moderate', 'Decreased seizure threshold has been reported in patients receiving pemoline concomitantly with antiepileptic medications.', 'DDInter', 'These drugs should be coadministered cautiously with careful clinical monitoring. Patients should be advised to notify their physician if they experience loss of seizure control.', 'Antagonism', 'These drugs should be coadministered cautiously with careful clinical monitoring.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71210/', '', 'Fenfluramine', 'Lisdexamfetamine, Solriamfetol, Dexmethylphenidate, Dextroamphetamine, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71124, 'Clonazepam', 'Penbutolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71211/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71125, 'Clonazepam', 'Pentazocine', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71212/', '', 'Naloxone', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71126, 'Clonazepam', 'Pentobarbital', 'Moderate', 'Barbiturates may increase the plasma clearance of clonazepam and thereby reduce its clinical effectiveness. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Also, clonazepam may increase the effectiveness of barbiturates. A case of respiratory depression and coma has been reported in a patient receiving high doses of both clonazepam and amobarbital.', 'DDInter', 'If these drugs are used together, close observation for altered clonazepam and barbiturate effects is indicated.', 'Metabolism, Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71213/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71127, 'Clonazepam', 'Perampanel', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71214/', '', 'Lacosamide, Perampanel', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71128, 'Clonazepam', 'Pergolide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71215/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71129, 'Clonazepam', 'Perindopril', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71216/', '', 'Bempedoic acid', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71130, 'Clonazepam', 'Perphenazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71217/', '', 'Amisulpride, Pimavanserin', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71131, 'Clonazepam', 'Phenelzine', 'Moderate', 'Limited clinical data suggest that concomitant use of clonazepam with monoamine oxidase inhibitors (MAOIs) may precipitate a hypertensive and/or flushing reaction. The mechanism of interaction has not been established. Phenelzine has been specifically implicated. Data for other combinations of MAOIs and benzodiazepines are not available.', 'DDInter', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine. Patients should be advised to notify their physician if they develop severe headaches or flushing.', 'Others', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71218/', '', 'St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71132, 'Clonazepam', 'Phenindamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71219/', '', 'Tiagabine, Ethotoin, Paramethadione, Mephenytoin, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, More', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71133, 'Clonazepam', 'Phenoxybenzamine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71220/', '', 'Cyclandelate, Isoxsuprine, Tolazoline', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71134, 'Clonazepam', 'Phentolamine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71221/', '', 'Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, Deferiprone, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71135, 'Clonazepam', 'Phenytoin', 'Moderate', 'Coadministration with some benzodiazepines may alter the serum concentrations of phenytoin. Phenytoin toxicity has been reported in patients treated with various benzodiazepines, including clobazam, chlordiazepoxide, clonazepam, and diazepam. Conversely, phenytoin may reduce the plasma concentrations of some benzodiazepines by inducing their metabolism via hepatic microsomal enzymes.', 'DDInter', 'Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary. Patients should be advised to contact their physician if they experience symptoms of hydantoin toxicity such as nausea, vomiting, tremors, ataxia, lethargy, slurred speech, visual disturbances, or changes in mental status. The potential for diminished or inadequate benzodiazepine effects should be considered during concomitant use with phenytoin.', 'Metabolism', 'Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71222/', '', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 'Ethotoin, Paramethadione, Phenacemide, Phenytoin, Trimethadione, Mephenytoin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71136, 'Clonazepam', 'Pimozide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71223/', '', 'Lacosamide', 'Amisulpride, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71137, 'Clonazepam', 'Pindolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71224/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Phenytoin, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71138, 'Clonazepam', 'Pipecuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', 'DDInter', 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71225/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71139, 'Clonazepam', 'Polythiazide', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71226/', '', 'Brivaracetam, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Ciclopirox, Vemurafenib, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, Oxytetracycline, Sulfamethizole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71140, 'Clonazepam', 'Pramipexole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71227/', '', 'Fosphenytoin, Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71141, 'Clonazepam', 'Pregabalin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71228/', '', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 'Lacosamide, Pregabalin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71142, 'Clonazepam', 'Prilocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71229/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71143, 'Clonazepam', 'Primidone', 'Moderate', 'Barbiturates may increase the plasma clearance of clonazepam and thereby reduce its clinical effectiveness. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Also, clonazepam may increase the effectiveness of barbiturates. A case of respiratory depression and coma has been reported in a patient receiving high doses of both clonazepam and amobarbital.', 'DDInter', 'If these drugs are used together, close observation for altered clonazepam and barbiturate effects is indicated.', 'Metabolism, Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71230/', '', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 'Lacosamide, Primidone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71144, 'Clonazepam', 'Probenecid', 'Minor', 'Limited clinical evidence suggests that benzodiazepine effects may have a more rapid onset and be more prolonged when probenecid is used concurrently. The mechanism may be related to interference with hepatic benzodiazepine conjugation. Patients should be monitored for prolonged or excessive CNS depression. Benzodiazepine dosage reductions may be necessary.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71231/', '', 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Ciclopirox, More', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71145, 'Clonazepam', 'Procaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71232/', '', 'Zinc sulfate, Zinc acetate, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71146, 'Clonazepam', 'Procarbazine', 'Moderate', 'Limited clinical data suggest that concomitant use of clonazepam with monoamine oxidase inhibitors (MAOIs) may precipitate a hypertensive and/or flushing reaction. The mechanism of interaction has not been established. Phenelzine has been specifically implicated. Data for other combinations of MAOIs and benzodiazepines are not available.', 'DDInter', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine. Patients should be advised to notify their physician if they develop severe headaches or flushing.', 'Others', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71233/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, More', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Mitotane, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71147, 'Clonazepam', 'Prochlorperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71234/', '', 'Amisulpride, Pimavanserin', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71148, 'Clonazepam', 'Procyclidine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71235/', '', 'Lacosamide, Paramethadione, Phenacemide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71149, 'Clonazepam', 'Promazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71236/', '', 'Amisulpride, Pimavanserin', 'Lacosamide, Paramethadione, Phensuximide, Phenacemide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71150, 'Clonazepam', 'Promethazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71237/', '', 'Lacosamide', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine, Pheniramine, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71151, 'Clonazepam', 'Propiomazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71238/', '', 'Ezogabine, Paramethadione, Phensuximide, Phenacemide, Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71152, 'Dextropropoxyphene', 'Clonazepam', 'Major', 'Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.', 'DDInter', 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.', 'Metabolism, Synergism', 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71239/', '', 'Naloxone', 'Fenfluramine, Perampanel, Eslicarbazepine, Lacosamide, Stiripentol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71153, 'Clonazepam', 'Propranolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71240/', '', 'Ivabradine', 'Ethotoin, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Fosphenytoin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71154, 'Clonazepam', 'Protriptyline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking clonazepam and tricyclic antidepressants.', 'DDInter', 'Patients should be monitored for excessive or prolonged CNS and respiratory depression. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, or confusion) and counseled to avoid activities requiring alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Patients should be monitored for excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71241/', '', 'St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71155, 'Clonazepam', 'Mepyramine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71242/', '', 'Lacosamide', 'Pheniramine, Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71156, 'Clonazepam', 'Quazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71243/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71157, 'Clonazepam', 'Quetiapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71244/', '', 'Ethotoin, Lacosamide, Mephenytoin', 'Amisulpride, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71158, 'Clonazepam', 'Quinapril', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71245/', '', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71159, 'Clonazepam', 'Ramelteon', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71246/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71160, 'Clonazepam', 'Ramipril', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71247/', '', 'Bempedoic acid', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71161, 'Clonazepam', 'Rapacuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', 'DDInter', 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71248/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71162, 'Clonazepam', 'Rasagiline', 'Moderate', 'Limited clinical data suggest that concomitant use of clonazepam with monoamine oxidase inhibitors (MAOIs) may precipitate a hypertensive and/or flushing reaction. The mechanism of interaction has not been established. Phenelzine has been specifically implicated. Data for other combinations of MAOIs and benzodiazepines are not available.', 'DDInter', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine. Patients should be advised to notify their physician if they develop severe headaches or flushing.', 'Others', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71249/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71163, 'Clonazepam', 'Remifentanil', 'Major', 'Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).', 'DDInter', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.', 'Synergism', 'The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71250/', '', 'Etomidate, Nitrous oxide', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71164, 'Clonazepam', 'Reserpine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71251/', '', 'Prazosin', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71165, 'Clonazepam', 'Rifabutin', 'Minor', 'Rifampin may decrease benzodiazepine serum levels. The mechanism is probably related to stimulation of the hepatic metabolism of benzodiazepines. Additionally, rifabutin may have an interaction with benzodiazepines similar to that of rifampin.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71252/', '', 'Capreomycin, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Tinidazole, More', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71166, 'Clonazepam', 'Rifampicin', 'Minor', 'Rifampin may decrease benzodiazepine serum levels. The mechanism is probably related to stimulation of the hepatic metabolism of benzodiazepines. Additionally, rifabutin may have an interaction with benzodiazepines similar to that of rifampin.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71253/', '', 'Capreomycin, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Rufinamide, Topiramate, Ezogabine, Cenobamate, Paramethadione, Methsuximide, Eslicarbazepine, Phensuximide, Phenacemide, Trimethadione, Ethosuximide, Vigabatrin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71167, 'Clonazepam', 'Rifapentine', 'Moderate', 'Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine. Enzyme activities may be induced within 4 days of the first dose and return to normal 14 days after discontinuation of rifapentine.', 'DDInter', 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.', 'Metabolism', 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71254/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Capreomycin, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71168, 'Clonazepam', 'Rilonacept', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71255/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71169, 'Clonazepam', 'Risperidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71256/', '', 'Amisulpride, Pimavanserin', 'Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71170, 'Clonazepam', 'Ritonavir', 'Moderate', 'The coadministration of ritonavir and benzodiazepines that are substrates of the CYP450 3A4 enzymatic pathway may result in elevated plasma concentrations of the latter. The mechanism is decreased clearance of benzodiazepines due to inhibition of CYP450 3A4 activity by ritonavir.', 'DDInter', 'While clinical data are not available for all agents in the class, the possibility of prolonged and/or increased pharmacologic effects of benzodiazepines, including sedation and respiratory depression, should be considered in patients receiving ritonavir therapy. It may be appropriate to use lower benzodiazepine dosages in these patients, or use agents that are not metabolized by the CYP450 3A4 pathway (e.g., lorazepam, oxazepam, temazepam).', 'Metabolism', 'While clinical data are not available for all agents in the class, the possibility of prolonged and/or increased pharmacologic effects of benzodiazepines, including sedation and respiratory depression, should be considered in patients receiving ritonavir therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71257/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More', 'Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Vigabatrin, Mephenytoin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71171, 'Clonazepam', 'Rocuronium', 'Moderate', 'Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.', 'DDInter', 'Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71258/', '', 'Botulinum toxin type A', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71172, 'Clonazepam', 'Ropinirole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71259/', '', 'Fosphenytoin, Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71173, 'Clonazepam', 'Ropivacaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71260/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71174, 'Clonazepam', 'Rotigotine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71261/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71175, 'Clonazepam', 'Rucaparib', 'Moderate', 'Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.', 'DDInter', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71262/', '', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Mitotane, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71176, 'Clonazepam', 'Rufinamide', 'Moderate', 'Rufinamide may modestly or moderately decrease the plasma concentrations and therapeutic effects of drugs that are CYP450 3A4 substrates. The mechanism is enhanced metabolism by CYP450 3A4 enzyme induction.', 'DDInter', 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose. Dose adjustments of the coadministered drug may be required if an interaction is suspected.', 'Metabolism', 'During concomitant treatment with rufinamide and drugs that are CYP450 3A4 substrates, it is recommended that patients should be monitored for 2 weeks when rufinamide is added to or withdrawn from therapy, or after increases of the dose.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71263/', '', 'Lacosamide, Rufinamide, Zonisamide', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71177, 'Clonazepam', 'Safinamide', 'Moderate', 'Limited clinical data suggest that concomitant use of clonazepam with monoamine oxidase inhibitors (MAOIs) may precipitate a hypertensive and/or flushing reaction. The mechanism of interaction has not been established. Phenelzine has been specifically implicated. Data for other combinations of MAOIs and benzodiazepines are not available.', 'DDInter', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine. Patients should be advised to notify their physician if they develop severe headaches or flushing.', 'Others', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71264/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71178, 'Clonazepam', 'Saquinavir', 'Moderate', 'Coadministration with saquinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by saquinavir.', 'DDInter', 'Caution is advised if saquinavir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever saquinavir is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if saquinavir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71265/', '', 'Ethotoin, Brivaracetam, Rufinamide, Valproic acid, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Fenfluramine, Phensuximide, Lamotrigine, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71179, 'Clonazepam', 'Sarilumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71266/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71180, 'Clonazepam', 'Satralizumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71267/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71181, 'Clonazepam', 'Secobarbital', 'Moderate', 'Barbiturates may increase the plasma clearance of clonazepam and thereby reduce its clinical effectiveness. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Also, clonazepam may increase the effectiveness of barbiturates. A case of respiratory depression and coma has been reported in a patient receiving high doses of both clonazepam and amobarbital.', 'DDInter', 'If these drugs are used together, close observation for altered clonazepam and barbiturate effects is indicated.', 'Metabolism, Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71268/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71182, 'Clonazepam', 'Secukinumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71269/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71183, 'Clonazepam', 'Selegiline', 'Moderate', 'Limited clinical data suggest that concomitant use of clonazepam with monoamine oxidase inhibitors (MAOIs) may precipitate a hypertensive and/or flushing reaction. The mechanism of interaction has not been established. Phenelzine has been specifically implicated. Data for other combinations of MAOIs and benzodiazepines are not available.', 'DDInter', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine. Patients should be advised to notify their physician if they develop severe headaches or flushing.', 'Others', 'Until more information is available, patients should be monitored for development of hypertension during coadministration of clonazepam with an MAOI or or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71270/', '', 'Lacosamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71184, 'Clonazepam', 'Selpercatinib', 'Moderate', 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71271/', '', 'Brivaracetam, Topiramate, Lamotrigine, Lacosamide, Levetiracetam, Ethotoin, Paramethadione, Perampanel, Vigabatrin, Mephenytoin, Stiripentol, More', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71185, 'Clonazepam', 'Sertraline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71272/', '', 'St. John''s Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71186, 'Clonazepam', 'Sevoflurane', 'Minor', 'Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71273/', '', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 'Etomidate, Nitrous oxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71187, 'Clonazepam', 'Sibutramine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71274/', '', 'Lamotrigine, Lacosamide, Tiagabine, Fosphenytoin', 'Dexfenfluramine, Ephedrine, Lorcaserin, Diethylpropion, Mazindol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71188, 'Clonazepam', 'Silodosin', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71275/', '', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, More', 'Solifenacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71189, 'Clonazepam', 'Siltuximab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71276/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71190, 'Clonazepam', 'Sirolimus', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71277/', '', 'Alteplase, Ascorbic acid, Potassium Iodide, Acetylcysteine, Nandrolone, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Ethotoin, Brivaracetam, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Lamotrigine, Ganaxolone, Phensuximide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71191, 'Clonazepam', 'Sodium bicarbonate', 'Minor', 'number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71278/', '', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More', 'Sorbitol, Sulfamethizole, Magnesium citrate, Sodium chloride, Neomycin, Sodium acetate, Zinc sulfate, Magnesium sulfate, Arginine, Sodium glycerophosphate, Zinc chloride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71192, 'Iodide I-123', 'Clonazepam', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', 'DDInter', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71279/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71193, 'Iodide I-131', 'Clonazepam', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', 'DDInter', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71280/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', 'Ibritumomab tiuxetan, Tositumomab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71194, 'Clonazepam', 'Sodium oxybate', 'Major', 'The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of sedative-hypnotic agents. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be anticipated.', 'DDInter', 'The use of sodium oxybate in combination with sedative-hypnotic agents is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71281/', '', 'Etomidate, Nitrous oxide, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71195, 'Clonazepam', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71282/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71196, 'Clonazepam', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71283/', '', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71197, 'Clonazepam', 'Somatotropin', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71284/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Lacosamide, Levetiracetam, Oxcarbazepine, Ethotoin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71198, 'Clonazepam', 'Sotalol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71285/', '', 'Ivabradine', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71199, 'Clonazepam', 'Stiripentol', 'Moderate', 'The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6. The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.', 'DDInter', 'Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use. Dosage adjustments may be required if increased plasma levels or effects are observed.', 'Metabolism', 'Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71286/', '', 'Lacosamide, Stiripentol', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (71200, 'Clonazepam', 'Succinylcholine', 'Minor', 'Benzodiazepines have variable effects on succinylcholine. Potentiation, attenuation and no effect have all been reported. Patients should be monitored closely for respiratory difficulty when these agents are used together.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/71287/', '', 'Botulinum toxin type A', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 1767369485);
